

Supplemental Table 1 The side effects of lenalidomide maintenance therapy in all the enrolled patients

Side effects	Mild	Severe (grade3-4)
Hematologic		
Neutropenia, Thrombocytopenia or anemia	1/7	0/7
Non hematologic		
Fatigue	1/7	0/7
Rash	0/7	0/7
Digestive tract syndrome (such as diarrhea and vommiting)	0/7	0/7
Dyspnea	0/7	0/7
Infections (such as pneumonia)	0/7	0/7

Supplemental Materials and Methods

SiRNA information: Three CRBN small interfering RNA (siRNA) was synthesized by GenePhama, China, we detected the most efficient one with the following sequences: 5'-GUUGCCCAGUGUAAGAUCUTT-3' (sense) and 5'-AGAUCUUACACUGGGCAACTT-3' (antisense). Nonspecific siRNA (NC siRNA) was also synthesized by GenePhama using the sequence: 5'-UUCUCCGAACGU-GUCACG-3' (sense) and 5'-ACGUGACACGUUCGGAGAATT-3' (antisense).

Follow up of MCL patients: The follow-up for all patients was as follows: during the induction period, patients received thorough measurements every three courses of chemotherapy including total body CT scan, bone marrow puncture and biopsy. Following auto-HSCT, patients received a total body CT scan every 3 months in the first year, every 6 months in the second year, and yearly beginning in the third year. If patients had bone marrow involvement at beginning of the disease, they received bone marrow puncture and biopsy each time. The end points of this study were disease progression and death.